IBTROZI (Taletrectinib) - IBTROZI is a next-generation ROS1 inhibitor approved for advanced ROS1+ NSCLC in the U S, Japan, and China[3] - The U S FDA approved IBTROZI on June 11, 2025[117, 120] - Since its U S launch, IBTROZI has achieved 432 new patient starts[16, 20, 120] - IBTROZI has a theoretical maximum gross market opportunity of approximately $4 billion[16] - Median Duration of Response (DOR) in TKI-naïve patients reached 50 months[24, 25] - Nuvation Bio entered an exclusive licensing agreement with Eisai for IBTROZI in Europe and additional countries, receiving up to ~$230 million in cash consideration[6] Safusidenib - Safusidenib is a potentially best-in-class mIDH1 inhibitor being evaluated in a pivotal study for high-grade and high-risk IDH1-mutant glioma[3, 4, 118, 120] - A Phase 1 study of Safusidenib in high-grade IDH1-mutant glioma showed a 17% confirmed objective response rate (cORR), including 2 complete responses (CRs)[83, 84] - A Phase 2 study of Safusidenib in low-grade IDH1-mutant glioma showed a 24-month progression-free survival (PFS) rate of 88%[71, 83, 84] Financial Status - Nuvation Bio has a robust pro forma cash balance of approximately $589 million, expected to provide a path to profitability without needing additional funding[3, 119]

NASDAQ: CPRX January 2026 Improving the Lives of Patients Living with Rare Diseases Safe Harbor This presentation contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are outside our control. All statements regarding our strategy, future operations, financial position, estimated revenues or losses, projected costs, prospects, plans, and objectives, other than statements of historical fact included in our filings with the U.S. Securities and Exchange Comm ...

Corporate Presentation for JPM January 2026 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (the "Act"). Forward-looking statements are statements that are not of historical fact and include, without limitation, statements regarding future events, our future financial condition, results of operations, business strategy and plans, prospective products (as well as their potential to achiev ...

EVERY BREAKTHROUGH BEGINS WITH BELIEF January 2026 Corporate Presentation Disclaimer Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current expectations and beliefs of the management of Neurogene, as well as assumptions made by, and ...

© 2 0 2 6 O R U K A T H E R A P E U T I C S Disclaimers The information contained in this presentation has been prepared by Oruka Therapeutics, Inc. (the "Company") and contains information pertaining to the business and operations of the Company. The information contained in this presentation: (a) is provided as at the date hereof, is subject to change without notice, and is based on publicly available information, internally developed data as well as third party information from other sources; (b) does no ...

Corporate Presentation Financial Discipline and Opportunistic Innovation * RYTELO® (imetelstat) is approved in the U.S. and the EU for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. See U.S. Prescribing Information and Medication Guide: https://pi.geron.com/products/US/pi/rytelo_pi.pdf; see Summary of Product Characteristics for RYTELO in the EU: https://pi.geron.com/products/rytelo/eu/rytelo_smpc_eu.pdf o $220M-$240M in expected ...

Bicycle Therapeutics Investor Presentation • January 2026 Forward-looking statements This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts", "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that a ...

ADMA Biologics Realizing the Potential of Specialty Biologics with Groundbreaking Immunotechnology January 2026 NASDAQ: ADMA Forward-Looking Statements This presentation contains "forward-looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. and its subsidiaries (collectively, "we," "our" or the "Company"), including, without limitation, statements that may predict, forecast, indicate, or imply future results, performan ...

January 9, 2026 Zanidatamab: Pivotal Phase 3 HERIZON-GEA-01 Trial Results in Gastroesophageal Adenocarcinoma (GEA) Innovating to Transform the Lives of Patients and Their Families Intended for U.S. investor audiences only. Intended for U.S. investor audiences only. 2 January 9, 2026 Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the C ...

KalVista Pharmaceuticals Corporate Overview January 2026 1 Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be ...